New combo aims to tackle tough breast cancer in patients with metabolic issues

NCT ID NCT05570253

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether adding the experimental drug evexomostat (SDX-7320) to standard chemotherapy (eribulin) works better than chemotherapy alone for people with metastatic triple-negative breast cancer who also have metabolic dysfunction (like insulin resistance). The study will enroll 55 participants and measure changes in insulin resistance, tumor response, and side effects. It is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: evexomostat (SDX-7320) combined with eribulin
What this could lead to: If it works, this could point toward a more effective treatment for people with triple-negative breast cancer who also have metabolic issues like insulin resistance.
What could go wrong: This is a small, early-phase trial with only 55 participants, so results may not apply to everyone. The drug combination may cause side effects or not improve outcomes over standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

BAPTIST ALLIANCE - MCI (Data Collection Only)
RECRUITING

Miami, Florida, 33143, United States
Emory University (Data Collection Only)
RECRUITING

Atlanta, Georgia, 30322, United States
Hackensack Meridian Health
RECRUITING

Hackensack, New Jersey, 07601, United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.